Proteomics

Dataset Information

0

Quantitative Phosphoproteomics Reveals Genistein as a Modulator of Cell Cycle and DNA Damage Response Pathways


ABSTRACT: Around one sixth of breast cancer cases are classified as triple-negative breast cancer (TNBC), named after the absence of the expression of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2); however, patients with TNBC suffer from poor clinical outcome and shortage of targeted therapy. Genistein, an estrogenic soy isoflavone, shows anti-cancer effects in TNBC cells such as inducing G2/M cell cycle arrest and apoptosis. However, the underlying mechanism of its anti-cancer effects is poorly understood and its elucidation can help the development of novel therapeutic strategies for TNBC. In this study, by combining isobaric tag-based TMT labeling with titanium dioxide-based phosphopeptide enrichment, we quantitated 5,445 phosphorylation sites on 2,008 phosphoproteins in a TNBC cell line, MDA-MB-231, upon genistein treatment. Our analysis revealed 332 genistein-regulated phosphorylation sites on 226 proteins. Our data show that genistein can regulate several biological processes during the cell cycle, including DNA replication, cohesin complex cleavage, and kinetochore formation. In the meantime, genistein can also activate DNA damage response, including activation of ATR and BRCA1 complex. Overall, for the first time, our study present the evidence that genistein could inhibit TNBC cell growth by regulating the cell cycle and DNA damage response. Our findings help elucidate the mechanisms through which genistein exerts its anti-cancer effects in TNBC cells.

INSTRUMENT(S): LTQ Orbitrap Velos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Mammary Gland Epithelial Cell

DISEASE(S): Breast Cancer

SUBMITTER: Yi Fang  

LAB HEAD: Jing Wang

PROVIDER: PXD002735 | Pride | 2016-01-26

REPOSITORIES: Pride

altmetric image

Publications

Quantitative phosphoproteomics reveals genistein as a modulator of cell cycle and DNA damage response pathways in triple-negative breast cancer cells.

Fang Yi Y   Zhang Qian Q   Wang Xin X   Yang Xue X   Wang Xiangyu X   Huang Zhen Z   Jiao Yuchen Y   Wang Jing J  

International journal of oncology 20160111 3


Around one sixth of breast cancer cases are classified as triple-negative breast cancer (TNBC), named after the absence of the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2); however, patients with TNBC suffer from poor clinical outcome and shortage of targeted therapy. Genistein, an estrogenic soy isoflavone, shows anticancer effects in TNBC cells such as inducing G2/M cell cycle arrest and apoptosis. However, the underlying  ...[more]

Similar Datasets

2018-01-08 | PXD003092 | Pride
2024-01-26 | PXD042268 | Pride
2019-12-18 | PXD007785 | Pride
2018-03-05 | PXD007637 | Pride
2016-12-14 | PXD003108 | Pride
2015-03-31 | E-GEOD-56325 | biostudies-arrayexpress
2015-03-31 | E-GEOD-56324 | biostudies-arrayexpress
2008-02-01 | E-ATMX-36 | biostudies-arrayexpress
2008-02-01 | E-ATMX-37 | biostudies-arrayexpress
2016-05-25 | PXD001812 | Pride